Emergent BioSolutions has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA) valued at $19.7 million to develop and manufacture cGMP lots of three Ebola monoclonal antibodies in CHO cell lines at a 2,000 liter scale. This contract is the first BARDA task order for an Ebola countermeasure awarded to Emergent under the Center for Innovation in Advanced Development and Manufacturing (CIADM) program. Under the scope of this two-year contract, the company wi...